{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:42:41Z","timestamp":1782456161977,"version":"3.54.5"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively novel class of drug for treating type 2 diabetes mellitus (T2DM) that inhibits glucose reabsorption in the renal proximal tubule to promote glycosuria and reduce blood glucose levels. SGLT2i has been clinically indicated for treating T2DM, with numerous recent publications focussing on both primary and secondary prevention of cardiovascular and renal events in Type 2 diabetic patients. The most recent clinical trials showed that SGLT2i have moderately significant beneficial effects on atherosclerotic major adverse cardiovascular events (MACE) in patients with histories of atherosclerotic cardiovascular disease. In this review and analysis, SGLT2i have however demonstrated clinically significant benefits in reducing hospitalisation for heart failure and worsening of chronic kidney disease (CKD) irrespective of pre-existing atherosclerotic cardiovascular disease or previous heart failure history. A meta-analysis suggests that all SGLT2 inhibitors demonstrated the therapeutic benefit on all-cause and cardiovascular mortality, as shown in EMPAREG OUTCOME study with a significant decrease in myocardial infarction, without increased stroke risk. All the above clinical trial recruited type 2 diabetic patients. This article aims to postulate and review the possible primary prevention role of SGLT2i in healthy individuals by reviewing the current literature and provide a prospective overview. The emphasis will include primary prevention of Type 2 Diabetes, Heart Failure, CKD, Hypertension, Obesity and Dyslipidaemia in healthy individuals, whom are defined as healthy, low or intermediate risks patients.<\/jats:p>","DOI":"10.3389\/fmed.2021.712671","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T05:22:42Z","timestamp":1629696162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?"],"prefix":"10.3389","volume":"8","author":[{"given":"Dan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owain","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleo","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquita S.","family":"Affandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxue","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bcp.2015.09.005","article-title":"SGLT2 inhibitors","volume":"101","author":"Dardi","year":"2016","journal-title":"Biochem Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/jcpt.12077","article-title":"The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors","volume":"38","author":"Cangoz","year":"2013","journal-title":"J Clin Pharm Ther."},{"key":"B5","article-title":"Sodium glucose co-transporter 2 inhibitors","author":"Health","year":"2018"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0234065","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLoS ONE."},{"key":"B7","volume-title":"Australian Type 2 Diabetes Management Algorithm","year":"2020"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-\u22122021","volume":"44","year":"2021","journal-title":"Diabetes Care."},{"key":"B9","unstructured":"SGLT2 Inhibitors (Gliflozins): Diabetes.co.uk.2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B11","article-title":"Guidelines for the prevention and control of type 2 diabetes in China","volume":"10","author":"Society","year":"2017","journal-title":"Chin J Diabetes Mellitus"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e3158","DOI":"10.1002\/dmrr.3158","article-title":"Standards of medical care for type 2 diabetes in China 2019","volume":"35","author":"Jia","year":"2019","journal-title":"Diabetes Metab Res Rev."},{"key":"B13","article-title":"Heart Failure Panel","volume":"46","author":"Association","year":"2018","journal-title":"Chin J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotaglifozin, the frst dual SGLT inhibitor: current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovascu Diabetol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1185\/03007995.2012.689956","article-title":"Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study","volume":"28","author":"Nicolle","year":"2012","journal-title":"Curr Med Res Opin."},{"key":"B16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e3223","DOI":"10.1002\/dmrr.3223","article-title":"Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes","volume":"36","author":"Zhou","year":"2020","journal-title":"Diabetes Metab Res Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in Type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1210\/jc.2019-00139","article-title":"SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission","volume":"104","author":"Hamblin","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/jcm10040571","article-title":"Effectiveness and safety of SGLT2 Inhibitors in clinical routine treatment of patients with diabetes mellitus Type 2","volume":"10","author":"Hopf","year":"2021","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"key":"B25","volume-title":"ALERT UPDATE. January 2020: Periprocedural diabetic ketoacidosis (DKA) with SGLT2 inhibitor use.","year":"2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.aace.2020.11.019","article-title":"Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors","volume":"7","author":"Vitale","year":"2021","journal-title":"AACE Clin Case Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis","volume":"70","author":"Yang","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"B29","article-title":"FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet)","author":"Administration","year":"2016"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/eurheartj\/ehaa1022","article-title":"Do SGLT2 inhibitors increase the risk of amputation?","volume":"42","author":"Vlachopoulos","year":"2021","journal-title":"Make haste slowly Eur Heart J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14740338.2020.1733967","article-title":"Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease","volume":"19","author":"Scheen","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013 glucose cotransporter 2 inhibitors for Type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"B38","unstructured":"Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank\n            ViswanathanM\n            BerkmanND\n            DrydenDM\n            HartlingL\n          24006553Rockville, MDAgency for Healthcare Research and Quality (US)2013"},{"key":"B39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with Type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MNH.0000000000000343","article-title":"Do efects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?","volume":"26","author":"Rajasekeran","year":"2017","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.3390\/ijms20235831","article-title":"Renal benefts of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes","volume":"20","author":"Nincevic","year":"2019","journal-title":"Int J Molr Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13854","article-title":"Efects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes","volume":"22","author":"Chilton","year":"2020","journal-title":"Diab Obes Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"058","DOI":"10.24966\/GGM-8662\/100058","article-title":"Metformin use beyond diabetes: reducing cardiovascular events in the healthy elderly","volume":"6","author":"Xu","year":"2020","journal-title":"J Gerontol Geriatr Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000324934","article-title":"Epidemiology of diabetic nephropathy","volume":"170","author":"Reutens","year":"2011","journal-title":"Contrib Nephrol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0254-6272(15)30003-0","article-title":"Efect of Huangshukuihua (Flos Abelmoschi Manihot) on diabetic nephropathy: a meta-analysis","volume":"35","author":"Yang","year":"2015","journal-title":"J Tradit Chin Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empaglifozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.7326\/M19-1638","article-title":"Diabetes technology: review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes","volume":"171","author":"Chamberlain","year":"2019","journal-title":"Ann Intern Med."},{"key":"B51","first-page":"15","article-title":"Chinese clinical practice guideline of diabetic kidney disease","volume":"11","author":"Association","year":"2019","journal-title":"Chin J Diab Mellitus"},{"key":"B52","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes."},{"key":"B53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/00325481.2019.1601404","article-title":"SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence","volume":"131","author":"Davidson","year":"2019","journal-title":"Postgrad Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/medicina55060268","article-title":"SGLT2 inhibitors: nephroprotective efcacy and side efects","volume":"55","author":"Garofalo","year":"2019","journal-title":"Medicina."},{"key":"B55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2017.03.006","article-title":"SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease","volume":"33","author":"Perico","year":"2017","journal-title":"Curr Opin Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Bae","year":"2019","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40620-016-0261-1","article-title":"The effect of dapaglifozin on renal function in patients with type 2 diabetes","volume":"29","author":"Kohan","year":"2016","journal-title":"J Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J Diabetes."},{"key":"B60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1477-7525-8-62","article-title":"Prevalence of chronic complications of type 2 diabetes mellitus in outpatients\u2013a cross-sectional hospital based survey in urban China","volume":"8","author":"Liu","year":"2010","journal-title":"Health Quality Life Outcomes."},{"key":"B61","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term efects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N Engl J Med."},{"key":"B62","first-page":"6","article-title":"An analysis of the correlation between tumors and death caused of diabetic inpatients in 15 provinces from 1991 to 2005","volume":"17","author":"Zhang","year":"2009","journal-title":"Chin J Diabetes."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e212LP","DOI":"10.2337\/dc16-1312","article-title":"Effect of Empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"B64","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","article-title":"Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes","volume":"17","author":"Matsutani","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in Type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with Type 2 diabetes mellitus and coronary artery disease","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation."},{"key":"B68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12933-016-0419-0","article-title":"Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design","volume":"15","author":"Singh","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","article-title":"Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial","volume":"16","author":"Natali","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-019-0910-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial","volume":"18","author":"Bonora","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.pcad.2020.04.003","article-title":"Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease","volume":"63","author":"Kario","year":"2020","journal-title":"Prog Cardiovascu Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e005686","DOI":"10.1161\/JAHA.117.005686","article-title":"Dixon DL: Effects of sodium-glucose cotransporter 2 Inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis","volume":"6","author":"Baker","year":"2017","journal-title":"J Am Heart Association."},{"key":"B74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, Phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"B76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-019-0912-3","article-title":"Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)","volume":"18","author":"Kinguchi","year":"2019","journal-title":"Cardiovascu Diabetol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-019-0929-7","article-title":"Grossman E: Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents.","volume":"18","author":"Fishman","year":"2019","journal-title":"Cardiovascu Diabetol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with Type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLoS ONE."},{"key":"B79","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (Low-Density Lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose Cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob -\/- mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fendo.2020.00190","article-title":"Prospect of sodium-glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with Type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.13747","article-title":"Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: a multicentre retrospective study","volume":"21","author":"Fadini","year":"2019","journal-title":"Diabetes Obes Metab."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.712671\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T05:22:50Z","timestamp":1629696170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.712671\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":85,"alternative-id":["10.3389\/fmed.2021.712671"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.712671","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"article-number":"712671"}}